| Rescuing High Avidity T Cells for Prostate Cancer Immunotherapy |
APR 2004 |
82 pages |
| Authors:
Pan Zheng; OHIO STATE UNIV COLUMBUS
|
 | This is the first annual report on the grant Rescuing high avidity T cells for prostate cancer immunotherapy". The purpose of the grant proposal is to rescue high avidity tumor-antigen specific T cells that can respond effectively to prostate cancer cells and delay the development of prostate cancer in the TRAMP mouse model. The innovative idea is based on the hypothesis that blockade of the T cell costimulatory pathway in ... |
|
| Proto-Oncogene PML and Tumor Evasion in Prostate Cancer |
NOV 2002 |
79 pages |
| Authors:
Pan Zheng; OHIO STATE UNIV RESEARCH FOUNDATION COLUMBUS
|
| This is the Final report on the grant "Proto-oncogene PML and tumor evasion in prostate cancer?" We proposed to identify the antigen presentation defects in human prostate cancer samples and to use mouse prostate cancer model (TRAMP mice) to study the immune regulation and immune tolerance in prostate cancer. In the past three years, we have completed the experiments proposed in the grant. We have shown that proto-oncogene PML and ... |
|
| Proto-oncogene PML and Tumor Evasion in Prostate Cancer |
NOV 2001 |
122 pages |
| Authors:
Pan Zheng; OHIO STATE UNIV COLUMBUS
|
| This is the second annual report on the grant "Proto-oncogene PML and tumor evasion in prostate cancer". The purpose of the grant proposal is to identify the molecular mechanisms of tumor evasion of host anti-tumor immunity. We proposed to identify the antigen presentation defects in human prostate cancer samples and to use mouse prostate cancer model (TRAMP mice) to study the immune regulation and immune tolerance in prostate cancer. In ... |
|
| Proto-oncogene PML and Tumor Evasion in Prostate Cancer |
NOV 2000 |
13 pages |
| Authors:
Pan Zheng; OHIO STATE UNIV COLUMBUS
|
| The peptides presented by class I human leukocyte antigen (HLA) are the primary targets on tumor cells for immune recognition by host cytotoxic T lymphocytes (CTL). Tumors can therefore avoid CTL recognition by down-regulation of cell surface HLA. However, the molecular mechanism of HLA down-regulation and its significance in progression of prostate carcinoma have not been determined. We have proposed to identify the antigen presentation defects in prostate cancer, to ... |
|
Reports by Author
